POSTERS ASCO 2024

Melanoma y cánceres de piel

Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.

Pembrolizumab (pembro) for locally advanced (LA) or recurrent/metastatic (R/M) cutaneous squamous cell carcinoma (cSCC): Long-term results of the phase 2 KEYNOTE-629 study.

Abstract: 9554 Poster Bd #: 338

Poster

Descargar

Autor
Eva Muñoz Couselo, MD, PhD

Hospital Vall d’Hebron and Vall d’Hebron Institute of Oncology (VHIO)

Compartir:

Una iniciativa científica de:

eco clover

Con el patrocinio de:

REGENERON